All Updates

All Updates

icon
Filter
Funding
M&A
Akili Interactive goes public on Nasdaq via SPAC deal; valued at USD 449 million
Mental Health Tech
Aug 22, 2022
This week:
Partnerships
Intuitive AI partner with Moda Center to implement Oscar Sort recycling technology
Waste Recovery & Management Tech
Yesterday
Management news
Funding
Minze Health raises USD 5.3 million in funding for product and market expansion; appoints new VP
Preventive Healthcare
Yesterday
Partnerships
Firefly Aerospace partners with True Anomaly for Space Force rapid-response mission launches
Space Travel and Exploration Tech
Yesterday
Funding
zkPass raises USD 12.5 million in Series A funding
Enterprise Blockchain Solutions
Yesterday
Partnerships
Ontada partners with Microsoft to process unstructured oncology data using Azure AI
Clinical Trial Technology
Yesterday
Product updates
Burcon unveils canola protein isolate for egg replacement
Plant-based Dairy & Egg
Yesterday
Product updates
Bene Meat Technologies produces first cultivated burger at parity with premium beef
Cell-cultured Meat
Yesterday
Geographic expansion
Regulation/policy
The Better Meat Co. expands to Asia with Singapore approval for Rhiza mycoprotein
Plant-based Meat
Yesterday
Listing
Pony.ai files for US IPO
Auto Tech
Yesterday
Product updates
MineOS launches DSR management 2.0
Digital Privacy Tools
Yesterday
Mental Health Tech

Mental Health Tech

Aug 22, 2022

Akili Interactive goes public on Nasdaq via SPAC deal; valued at USD 449 million

Funding
M&A

<ul><li>Digital Therapeutics (DTx) provider Akili Interactive has completed its merger with Social Capital Suvretta Holdings Corp. (SCS), a special purpose acquisition company (SPAC). The combined entity is listed on the Nasdaq under the ticker symbol “AKLI”. The deal was previously reported to have a transaction value of USD 1 billion.</ul>

  • Akili’s stock opened trading on Monday at a value of USD 36 per share but fell below USD 20 during trading hours. The listed entity opened trading with a valuation of USD 448.6 million.

  • The transaction brought in USD 163 million in gross proceeds prior to paying advisory fees and transaction expenses. The funds will be used to launch the company’s solution EndeavorRx, an FDA approved DTx for children aged 8 – 12 with attention-related issues. The funds will also be used to support its research initiatives such as its late-stage development of solutions targeting neuropsychiatric disorders. The company notes that the funds should support two years of operations without any revenue from its DTx which has a planned launch for Q4 of 2022.

  • Akili CEO and co-founder, Eddie Martucci, will continue to lead the management team and serve on its board while Chamath Palihapitiya, Chairman and CEO of SCS, will become chair of Akili’s board.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.